Mechanisms activated by kidney disease and the loss of muscle mass
- PMID: 11728972
- DOI: 10.1053/ajkd.2001.29249
Mechanisms activated by kidney disease and the loss of muscle mass
Abstract
The daily turnover of cellular proteins is large, with amounts equivalent to the protein contained in 1.0 to 1.5 kg of muscle. Consequently, even a small, persistent increase in the rate of protein degradation or decrease in protein synthesis will result in substantial loss of muscle mass. Activation of protein degradation in the ubiquitin-proteasome system is the mechanism contributing to loss of muscle mass in kidney disease. Because other catabolic conditions also stimulate this system to cause loss of muscle mass, the identification of activating signals is of interest. A complication of kidney disease, metabolic acidosis, activates this system in muscle by a process that requires glucocorticoids. The influence of inflammatory cytokines on this system in muscle is more complicated, as evidence indicates that cytokines suppress the system, but glucocorticoids block the effect of cytokines to slow protein breakdown in the system. New information identifying mechanisms that activate protein breakdown and the rebuilding of muscle fibers would lead to therapies that successfully prevent the loss of muscle mass in kidney disease and other catabolic illnesses.
Similar articles
-
Mechanisms activating proteolysis to cause muscle atrophy in catabolic conditions.J Ren Nutr. 2003 Apr;13(2):149-52. doi: 10.1053/jren.2003.50019. J Ren Nutr. 2003. PMID: 12671840 Review.
-
Cellular mechanisms controlling protein degradation in catabolic states.Miner Electrolyte Metab. 1997;23(3-6):194-7. Miner Electrolyte Metab. 1997. PMID: 9387115 Review.
-
Proteolysis, the ubiquitin-proteasome system, and renal diseases.Am J Physiol Renal Physiol. 2003 Jul;285(1):F1-8. doi: 10.1152/ajprenal.00244.2002. Am J Physiol Renal Physiol. 2003. PMID: 12788783 Review.
-
Metabolic acidosis stimulates protein metabolism in uremia.Miner Electrolyte Metab. 1996;22(1-3):62-5. Miner Electrolyte Metab. 1996. PMID: 8676827 Review.
-
Cellular mechanisms causing loss of muscle mass in kidney disease.Semin Nephrol. 2004 Sep;24(5):484-7. doi: 10.1016/j.semnephrol.2004.06.014. Semin Nephrol. 2004. PMID: 15490416 Review.
Cited by
-
Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease.Clin J Am Soc Nephrol. 2011 Oct;6(10):2395-402. doi: 10.2215/CJN.03730411. Epub 2011 Sep 1. Clin J Am Soc Nephrol. 2011. PMID: 21885787 Free PMC article.
-
Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study.Int J Cardiol. 2016 Feb 15;205:43-49. doi: 10.1016/j.ijcard.2015.12.002. Epub 2015 Dec 11. Int J Cardiol. 2016. PMID: 26710332 Free PMC article. Clinical Trial.
-
Brain-derived neurotrophic factor (BDNF): a multifaceted marker in chronic kidney disease.Clin Exp Nephrol. 2022 Dec;26(12):1149-1159. doi: 10.1007/s10157-022-02268-z. Epub 2022 Aug 28. Clin Exp Nephrol. 2022. PMID: 36030459 Review.
-
Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem.ScientificWorldJournal. 2013 Dec 5;2013:643954. doi: 10.1155/2013/643954. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24382946 Free PMC article. Review.
-
Chapter 3: Management of progression and complications of CKD.Kidney Int Suppl (2011). 2013 Jan;3(1):73-90. doi: 10.1038/kisup.2012.66. Kidney Int Suppl (2011). 2013. PMID: 25598999 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical